Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future

por Betof Warner, Allison, Corrie, Pippa G., Hamid, Omid
Publicado 2023

Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma

por Loo, Kimberly, Smithy, James W., Postow, Michael A., Betof Warner, Allison
Publicado 2022

Case report: Later onset of NRAS-mutant metastatic melanoma in a patient with a partially-excised giant congenital melanocytic nevus

por Costa, Bruno Almeida, Zibara, Victor, Singh, Vasundhara, Hamid, Omid, Gandhi, Sonal, Moy, Andrea P., Betof Warner, Allison S.
Publicado 2022

Efficacy of immunotherapy for melanoma brain metastases in patients with concurrent corticosteroid exposure

por Tringale, Kathryn R, Reiner, Anne S, Sehgal, Ryka R, Panageas, Katherine, Betof Warner, Allison S, Postow, Michael A, Moss, Nelson S
Publicado 2023

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

por Chapman, Paul B, Jayaprakasam, Vetri Sudar, Panageas, Katherine S, Callahan, Margaret, Postow, Michael A, Shoushtari, Alexander N, Wolchok, Jedd D, Betof Warner, Allison
Publicado 2021

Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade

por Beattie, Jason, Rizvi, Hira, Fuentes, Paige, Luo, Jia, Schoenfeld, Adam, Lin, I-Hsin, Postow, Michael, Callahan, Margaret, Voss, Martin H, Shah, Neil J, Betof Warner, Allison, Chawla, Mohit, Hellmann, Matthew D
Publicado 2021

Quantitative cerebrospinal fluid circulating tumor cells are a potential biomarker of response for proton craniospinal irradiation for leptomeningeal metastasis

por Wijetunga, N Ari, Boire, Adrienne, Young, Robert J, Yamada, Yoshiya, Wolden, Suzanne, Yu, Helena, Kris, Mark, Seidman, Andrew, Betof-Warner, Allison, Diaz, Maria, Reiner, Anne, Malani, Rachna, Pentsova, Elena, Yang, Jonathan T
Publicado 2021

Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness

por Hirschhorn, Daniel, Betof Warner, Allison, Maniyar, Rachana, Chow, Andrew, Mangarin, Levi M.B., Cohen, Adam D., Hamadene, Linda, Rizzuto, Gabrielle A., Budhu, Sadna, Suek, Nathan, Liu, Cailian, Houghton, Alan N., Merghoub, Taha, Wolchok, Jedd D.
Publicado 2021

Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy

por Halle, Briana Rose, Betof Warner, Allison, Zaman, Farzana Y, Haydon, Andrew, Bhave, Prachi, Dewan, Anna K, Ye, Fei, Irlmeier, Rebecca, Mehta, Paras, Kurtansky, Nicholas R, Lacouture, Mario E, Hassel, Jessica C, Choi, Jacob S, Sosman, Jeffrey A, Chandra, Sunandana, Otto, Tracey S, Sullivan, Ryan, Mooradian, Meghan J, Chen, Steven T, Dimitriou, Florentia, Long, Georgina, Carlino, Matteo, Menzies, Alexander, Johnson, Douglas B, Rotemberg, Veronica M
Publicado 2021

Early Use of High-Dose Glucocorticoid for the Management of irAE Is Associated with Poorer Survival in Patients with Advanced Melanoma Treated with Anti–PD-1 Monotherapy

por Bai, Xue, Hu, Jiani, Betof Warner, Allison, Quach, Henry T., Cann, Christopher G., Zhang, Michael Z., Si, Lu, Tang, Bixia, Cui, Chuanliang, Yang, Xiaoling, Wei, Xiaoting, Pallan, Lalit, Harvey, Catriona, Manos, Michael P., Ouyang, Olivia, Kim, Michelle S., Kasumova, Gyulnara, Cohen, Justine V., Lawrence, Donald P., Freedman, Christine, Fadden, Riley M., Rubin, Krista M., Sharova, Tatyana, Frederick, Dennie T., Flaherty, Keith T., Rahma, Osama E., Long, Georgina V., Menzies, Alexander M., Guo, Jun, Shoushtari, Alexander N., Johnson, Douglas B., Sullivan, Ryan J., Boland, Genevieve M.
Publicado 2021

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors

por Guidon, Amanda C, Burton, Leeann B, Chwalisz, Bart K, Hillis, James, Schaller, Teilo H, Amato, Anthony A, Betof Warner, Allison, Brastianos, Priscilla K, Cho, Tracey A, Clardy, Stacey L, Cohen, Justine V, Dietrich, Jorg, Dougan, Michael, Doughty, Christopher T, Dubey, Divyanshu, Gelfand, Jeffrey M, Guptill, Jeffrey T, Johnson, Douglas B, Juel, Vern C, Kadish, Robert, Kolb, Noah, LeBoeuf, Nicole R, Linnoila, Jenny, Mammen, Andrew L, Martinez-Lage, Maria, Mooradian, Meghan J, Naidoo, Jarushka, Neilan, Tomas G, Reardon, David A, Rubin, Krista M, Santomasso, Bianca D, Sullivan, Ryan J, Wang, Nancy, Woodman, Karin, Zubiri, Leyre, Louv, William C, Reynolds, Kerry L
Publicado 2021

Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma

por Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tetzlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, Tawbi, Hussein A.
Publicado 2023

Neoadjuvant relatlimab and nivolumab in resectable melanoma

por Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tetzlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, Tawbi, Hussein A.
Publicado 2022